α7 Receptor PAM
Bionomic is developing a small molecule alpha 7 nicotinic acetylcholine receptor (α7 nAChR) positive allosteric modulator program for the treatment of cognitive impairment in Alzheimer’s disease (AD). These molecules may be applicable to other neurodegenerative and psychiatric diseases where there is a need to restore memory function such as Parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder (ADHD). Compounds produced in this program have been effective in several animal models of impaired learning and memory over a broad dose range and have an excellent safety profile in such animal models.
Strategic Partnership with MSD
In 2014 Bionomics entered into an exclusive Research Collaboration and License Agreement with MSD (known as Merck & Co., Inc., Rahway NJ, USA in the US and Canada), to develop α7 Receptor PAM targeting cognitive dysfunction associated with Alzheimer’s disease and other CNS conditions.
MSD funds all research and clinical development, and worldwide commercialization of any resulting products. This collaboration generated payments of $20M upfront and $10M for a Phase 1 milestone. Bionomics is eligible to receive up to $465M in additional milestone payments for certain development and commercial milestones plus royalties on net sales of licensed drugs.
Bionomics has a lengthy history of successful alliances with industry and academia. We are open to expressions of interest with respect to partnership at all stages of development.